EP3070097A3 - Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis - Google Patents

Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis Download PDF

Info

Publication number
EP3070097A3
EP3070097A3 EP16164584.1A EP16164584A EP3070097A3 EP 3070097 A3 EP3070097 A3 EP 3070097A3 EP 16164584 A EP16164584 A EP 16164584A EP 3070097 A3 EP3070097 A3 EP 3070097A3
Authority
EP
European Patent Office
Prior art keywords
citrullinated peptides
rheumatoid arthritis
diagnosing
novel
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16164584.1A
Other languages
English (en)
French (fr)
Other versions
EP3070097A2 (de
Inventor
Nicholas Chi-Kwan Ling
Shui Long Wang
Dunrui Wang
Sharat Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of EP3070097A2 publication Critical patent/EP3070097A2/de
Publication of EP3070097A3 publication Critical patent/EP3070097A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
EP16164584.1A 2009-03-30 2010-03-26 Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis Withdrawn EP3070097A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16484009P 2009-03-30 2009-03-30
US24349609P 2009-09-17 2009-09-17
US25505809P 2009-10-26 2009-10-26
EP10722838A EP2414390A2 (de) 2009-03-30 2010-03-26 Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP10722838A Division EP2414390A2 (de) 2009-03-30 2010-03-26 Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis

Publications (2)

Publication Number Publication Date
EP3070097A2 EP3070097A2 (de) 2016-09-21
EP3070097A3 true EP3070097A3 (de) 2016-11-23

Family

ID=42651163

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16164584.1A Withdrawn EP3070097A3 (de) 2009-03-30 2010-03-26 Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis
EP10722838A Withdrawn EP2414390A2 (de) 2009-03-30 2010-03-26 Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10722838A Withdrawn EP2414390A2 (de) 2009-03-30 2010-03-26 Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis

Country Status (8)

Country Link
US (2) US8519096B2 (de)
EP (2) EP3070097A3 (de)
AU (1) AU2010234942B2 (de)
BR (2) BR122013006960A2 (de)
CA (1) CA2757444A1 (de)
IL (2) IL225538A0 (de)
NZ (2) NZ608489A (de)
WO (1) WO2010117694A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404932B2 (en) * 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
HUE044239T2 (hu) 2008-03-27 2019-10-28 Purdue Research Foundation Kollagén-kötõ szintetikus peptidoglikánok, elõállításuk és alkalmazási eljárásaik
EP2402368A1 (de) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histoncitrullinierte Peptide und deren Verwendungen
CA2817847C (en) * 2010-11-12 2018-02-13 The Johns Hopkins University Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
GB201101740D0 (en) 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
US20150218546A1 (en) * 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment
ES2560012T3 (es) * 2011-05-10 2016-02-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
EP2527841A1 (de) 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Verfahren zur Diagnose rheumatoider Arthritis
WO2012163768A1 (en) * 2011-05-27 2012-12-06 Nordic Bioscience A/S Detection of diagnostic peptides
WO2013105721A1 (ko) * 2012-01-13 2013-07-18 가톨릭대학교 산학협력단 류마티스 관절염 진단 키트
US9347941B2 (en) 2012-01-13 2016-05-24 Catholic University Industry-Academic Cooperation Foundation Diagnosis kit for rheumatoid arthritis
US20130274125A1 (en) * 2012-04-16 2013-10-17 Bio-Rad Laboratories Inc. Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
WO2014141244A1 (en) * 2013-03-12 2014-09-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
EP2970509B1 (de) 2013-03-15 2020-05-13 Purdue Research Foundation Extrazelluläre matrix zur bindung synthetischer peptidglycane
CA2923553C (en) 2013-09-13 2023-05-23 Soligenix, Inc. Novel peptides and analogs for use in the treatment of oral mucositis
US11311598B2 (en) 2013-09-13 2022-04-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
EP3311176A4 (de) 2015-06-18 2019-03-13 Cedars-Sinai Medical Center Rolle von citrullinierung bei der diagnose von erkrankungen
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
WO2019010484A2 (en) 2017-07-07 2019-01-10 Symic Ip, Llc SYNTHETIC BIOCONJUGATES
CN110862450A (zh) * 2018-08-28 2020-03-06 东莞光极生物科技有限公司 基于cii的环状多肽及其应用
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
CN110041404B (zh) * 2019-04-08 2020-10-09 北京大学人民医院(北京大学第二临床医学院) 瓜氨酸化抗原修饰肽及其应用
CN114573663B (zh) * 2019-08-27 2023-08-11 广东菲鹏生物有限公司 瓜氨酸肽及其应用、类风湿关节炎的检测试剂与试剂盒
WO2021038283A1 (en) * 2019-08-30 2021-03-04 Universidad De Chile Autoantigenic peptides (calvicifiv), presented by tolerogenic dentritic cells, useful for the personalized treatment of rheumatoid arthritis
CN113004421B (zh) * 2021-02-18 2022-05-17 青岛硕景生物科技有限公司 一种检测抗瓜氨酸肽抗体的ccp抗原及其制备方法
CA3220978A1 (en) * 2021-06-01 2022-12-08 Lars Klareskog Novel peptide mimics and their use
CN115060897A (zh) * 2021-07-01 2022-09-16 浙江大学 一种检测抗Prelamin A/C-IgG抗体的试剂盒
WO2024117967A1 (en) * 2022-12-01 2024-06-06 Dubnovitsky Anatoly Peptide mimics and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028344A2 (en) * 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
WO2007000320A2 (de) * 2005-06-27 2007-01-04 Orgentec Diagnostika Gmbh Verfahren zur diagnose von rheumatischen erkrankungen
WO2009010409A1 (en) * 2007-07-13 2009-01-22 Celecure As Novel inhibitor of angiogenesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
AU2004216925B2 (en) * 2003-03-07 2010-04-22 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028344A2 (en) * 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
WO2007000320A2 (de) * 2005-06-27 2007-01-04 Orgentec Diagnostika Gmbh Verfahren zur diagnose von rheumatischen erkrankungen
WO2009010409A1 (en) * 2007-07-13 2009-01-22 Celecure As Novel inhibitor of angiogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BANG HOLGER ET AL: "Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis", ARTHRITIS & RHEUMATISM, vol. 56, no. 8, August 2007 (2007-08-01), pages 2503 - 2511, XP002599084, ISSN: 0004-3591 *
NICAISE ROLAND PASCALE ET AL: "Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.", ARTHRITIS RESEARCH & THERAPY 2008 LNKD- PUBMED:19077182, vol. 10, no. 6, 2008, pages R142, XP002599085, ISSN: 1478-6362 *

Also Published As

Publication number Publication date
US20120295280A1 (en) 2012-11-22
WO2010117694A2 (en) 2010-10-14
IL225538A0 (en) 2013-06-27
CA2757444A1 (en) 2010-10-14
BR122013006960A2 (pt) 2019-10-15
US20140170683A1 (en) 2014-06-19
US8519096B2 (en) 2013-08-27
WO2010117694A3 (en) 2011-01-20
EP3070097A2 (de) 2016-09-21
EP2414390A2 (de) 2012-02-08
BRPI1013179A2 (pt) 2019-09-24
NZ595310A (en) 2013-05-31
NZ608489A (en) 2014-08-29
AU2010234942A1 (en) 2011-10-27
AU2010234942B2 (en) 2015-03-05
IL215337A (en) 2017-02-28
IL215337A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
WO2010117694A3 (en) Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
EP4335932A3 (de) Verfahren zur überwachung von zuständen durch sequenzanalyse
WO2011142836A3 (en) Assays for the detection of genotype, mutations, and/or aneuploidy
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
EP3239305A3 (de) Verwendung von mikrovesikeln bei der diagnose und prognose von medizinischen krankheiten und leiden
WO2013033629A3 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2012017466A8 (en) Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
WO2009024691A3 (fr) Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal
WO2011119934A3 (en) Methods and materials for detecting colorectal neoplasm
JP2011527429A5 (de)
EP2727935A3 (de) Mit Frühstadium und anderen Stadien von Brustkrebs assoziierte Serummarker
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
JP2012522232A5 (de)
WO2009015294A8 (en) Biomarkers for human papillomavirus-associated cancers
WO2009126969A3 (en) Biomarkers for endometrial disease
EP2582849A4 (de) Nachweis von nukleinsäuren und proteinen
EP4257982A3 (de) Biomarker zur diagnose von lungenkrebs
WO2009057294A1 (ja) 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法
WO2017218677A3 (en) Identification and medical applications of anti-citrullinated-protein antibodies in rheumatoid arthritis
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
Jefferson et al. Has the circulating permeability factor in primary FSGS been found?
EP1912066A4 (de) Hilfsverfahren zur diagnose und therapie von krebs mit nucleolin
WO2012089868A3 (es) Determinación de niveles de péptidos inmunogénicos del gluten en muestras humanas
WO2009025080A1 (ja) 大腸癌マーカポリペプチド、及び大腸癌の診断方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2414390

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/47 20060101AFI20161018BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NESTEC S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170524